We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
I Mab
7 own
2 watching
Current Price
$3.11
$0.12
(4.01%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
26.01M
52-Week High
12.7588
52-Week Low
2.73
Average Volume
0.13M
Dividend Yield
--
P/E Ratio
20.367
Market Capitalization26.01M52-Week High12.758852-Week Low2.73Average Volume0.13MDividend Yield--P/E Ratio20.367What does the I Mab do?
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People s Republic of China.
Read More
News & Events about I Mab.
PR Newswire
28days ago
I-MAB Filed 2022 Annual Report on Form 20-F I-MAB Filed 2022 Annual Report on Form 20-F PR Newswire GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ('I-Mab' or the 'Company') (Nasdaq: IMAB), a clinical-stage...
PR Newswire
1month ago
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 PR Newswire GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire...
PR Newswire
1month ago
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon PR Newswire GAITHERSBURG, Md. and SHANGHAI, April 25, 2023 Award is an important victory for I-Mab and its shareholders on multiple...
PR Newswire
1month ago
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China PR Newswire GAITHERSBURG, Md. and SHANGHAI, April 24, 2023...
PR Newswire
1month ago
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 PR Newswire GAITHERSBURG, Md. and SHANGHAI, March 31, 2023 Strategic...
Frequently Asked Questions
Frequently Asked Questions
What is I Mab share price today?
Can Indians buy I Mab shares?
How can I buy I Mab shares from India?
Can Fractional shares of I Mab be purchased?
What are the documents required to start investing in I Mab stocks?
What is today’s traded volume of I Mab?
What is today’s market capitalisation of I Mab?
What is the 52-Week High and Low Range of I Mab?
What percentage is I Mab down from its 52-Week High?
What percentage is I Mab up from its 52-Week Low?
Current Price
$3.11
$0.12
(4.01%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.